Naproxen - Iroko Pharmaceuticals

Drug Profile

Naproxen - Iroko Pharmaceuticals

Alternative Names: IP 890; Nano-formulated naproxen - Iroko Pharmaceuticals; SoluMatrix® Naproxen

Latest Information Update: 23 Feb 2016

Price : $50

At a glance

  • Originator iCeutica
  • Developer Iroko Pharmaceuticals
  • Class Antipyretics; Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Musculoskeletal pain
  • No development reported Dental pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2013 Short review: double checked that the results for dental pain were actually presented at a rheumatology conference. Same results are on CT.gov so all correct.
  • 01 Mar 2013 Iroko Pharmaceuticals plans phase III trials for Musculoskeletal pain (associated with osteoarthritis)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top